基本信息
views: 1
Career Trajectory
Bio
Research area and projects
Our overarching aim is to increase the natural production of insulin to combat type-2 diabetes (T2D). T2D in Singapore, very much like the rest of Asia, is largely characterized by insulin insufficiency that stems from a loss of pancreatic insulin-producing cell (beta-cell) mass and function. It is becoming increasingly clear that the best way to combat diabetic complications is to ensure that the endogenous source of insulin remains robust so as to keep blood glucose levels within a narrow band. Thus far, no artificial system is able to achieve this effectively. Our multi-disciplinary and collaborative approach, which involves material scientists, engineers and surgeons, brings us a step closer to our vision of bringing direct benefit to our patients here. The beta-cell drug target discovery team in my laboratory is focused on determining the molecular underpinnings of beta-cell failure so as to identify new drug targets to mitigate loss of insulin production during T2D. Our cell therapy and transplantation team seeks to deliver superior beta-cell transplant strategies (effective, sustainable, less-invasive and low-risk) that will increase the endogenous insulin provision to a patient, making a patient less-reliant on insulin injections, thereby improving quality of life.
Our key projects for drug target discovery include (i) identifying the precise role of immune cells in pancreatic islets, the latter being the site of where beta-cell reside in. We believe that modulation of islet immune cell function may be a possible therapeutic avenue for preventing loss of insulin secretion; (ii) elucidating the mechanism of saturated fatty acid induced beta-cell stress and toxicity in diabetes. Saturated fatty acids are far more damaging to beta-cells compared to unsaturated fatty acids but the exact reason for this is still nebulous. Understanding molecular changes between the two types of fatty acid may hold the key to preserving beta-cell survival and function in T2D; (iii) determining dynamisms of pancreatic islet vasculature and how it relates to beta-cell function. Islet blood vessels not only carry insulin throughout the body but also provide nutrients and oxygen to beta-cells. Insufficient blood supply will first and foremost trigger hypoxic pathways in beta-cells leading to dysfunction and, if persistent, even death. Measuring its extent in diabetes and thereafter mitigating its’ pathway, including downstream effects on DNA, may hold promise to preventing beta-cell failure and insulin insufficiency in diabetes.
Our overarching aim is to increase the natural production of insulin to combat type-2 diabetes (T2D). T2D in Singapore, very much like the rest of Asia, is largely characterized by insulin insufficiency that stems from a loss of pancreatic insulin-producing cell (beta-cell) mass and function. It is becoming increasingly clear that the best way to combat diabetic complications is to ensure that the endogenous source of insulin remains robust so as to keep blood glucose levels within a narrow band. Thus far, no artificial system is able to achieve this effectively. Our multi-disciplinary and collaborative approach, which involves material scientists, engineers and surgeons, brings us a step closer to our vision of bringing direct benefit to our patients here. The beta-cell drug target discovery team in my laboratory is focused on determining the molecular underpinnings of beta-cell failure so as to identify new drug targets to mitigate loss of insulin production during T2D. Our cell therapy and transplantation team seeks to deliver superior beta-cell transplant strategies (effective, sustainable, less-invasive and low-risk) that will increase the endogenous insulin provision to a patient, making a patient less-reliant on insulin injections, thereby improving quality of life.
Our key projects for drug target discovery include (i) identifying the precise role of immune cells in pancreatic islets, the latter being the site of where beta-cell reside in. We believe that modulation of islet immune cell function may be a possible therapeutic avenue for preventing loss of insulin secretion; (ii) elucidating the mechanism of saturated fatty acid induced beta-cell stress and toxicity in diabetes. Saturated fatty acids are far more damaging to beta-cells compared to unsaturated fatty acids but the exact reason for this is still nebulous. Understanding molecular changes between the two types of fatty acid may hold the key to preserving beta-cell survival and function in T2D; (iii) determining dynamisms of pancreatic islet vasculature and how it relates to beta-cell function. Islet blood vessels not only carry insulin throughout the body but also provide nutrients and oxygen to beta-cells. Insufficient blood supply will first and foremost trigger hypoxic pathways in beta-cells leading to dysfunction and, if persistent, even death. Measuring its extent in diabetes and thereafter mitigating its’ pathway, including downstream effects on DNA, may hold promise to preventing beta-cell failure and insulin insufficiency in diabetes.
Research Interests
Papers共 109 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Applied Physiology Nutrition and Metabolismno. 9 (2024): 1163-1174
Vanessa Yu,Fiona Yong, Angellica Marta,Sanjay Khadayate,Adrien Osakwe,Supriyo Bhattacharya,Sneha S. Varghese,Pauline Chabosseau, Sayed M. Tabibi,Keran Chen,Eleni Georgiadou,Nazia Parveen,Mara Suleiman, Zoe Stamoulis,Lorella Marselli,Carmela De Luca,Marta Tesi, Giada Ostinelli,Luis Delgadillo-Silva,Xiwei Wu,Yuki Hatanaka,Alex Montoya,James Elliott,Bhavik Patel, Nikita Demchenko,Chad Whilding,Petra Hajkova, Pavel Shliaha,Holger Kramer,Yusuf Ali,Piero Marchetti,Robert Sladek,Sangeeta Dhawan,Dominic J. Withers,Guy A. Rutter,Steven J. Millership
Zun Siong Low,Damien Chua,Hong Sheng Cheng,Rachel Tee,Wei Ren Tan, Christopher Ball,Norliza Binte Esmail Sahib,Ser Sue Ng, Jing Qu,Yingzi Liu,Haiyu Hong,Chaonong Cai, Nandini Chilagondanahalli Lakshmi Rao,Aileen Wee,Mark Dhinesh Muthiah,Zoe Bichler,Barbara Mickelson,Mei Suen Kong, Vanessa Shiyun Tay,Zhuang Yan,Jiapeng Chen,Aik Seng Ng,Yun Sheng Yip,Marcus Ivan Gerard Vos, Nicole Ashley Tan, Dao Liang Lim,Debbie Xiu En Lim,Manesh Chittezhath,Jadegoud Yaligar,Sanjay Kumar Verma,Harish Poptani,Xue Li Guan,Sambasivam Sendhil Velan,Yusuf Ali,Liang Li, Nguan Soon Tan,Walter Wahli
Vanessa Yu,Fiona Yong,Keran Chen,Eleni Georgiadou,Nazia Parveen, Angellica Marta,Sanjay Khadayate, Zoe Stamoulis,Lorella Marselli,Carmela De Luca,Mara Suleiman,Yuki Hatanaka,Alex Montoya,James Elliott,Bhavik Patel, Nikita Demchenko,Chad Whilding,Petra Hajkova, Pavel Schliaha,Holger Kramer,Yusuf Ali,Piero Marchetti,Sangeeta Dhawan,Dominic J. Withers,Guy A. Rutter,Steven J. Millership
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Life sciences (2023): 121436-121436
Biomoleculesno. 10 (2023): 1445-1445
Casandra Ai Zhu Tan,Kelvin Kian Long Chong, Daryl Yu Xuan Yeong, Celine Hui Min Ng,Muhammad Hafiz Ismail,Zhei Hwee Yap,Varnica Khetrapal, Vanessa Shi Yun Tay,Daniela I. Drautz-Moses,Yusuf Ali,Swaine L. Chen,Kimberly A. Kline
MBio (2023)
Frontiers in endocrinology (2023): 1214230
Acta pharmaceutica sinica Bno. 5 (2023): 1887-1902
Load More
Author Statistics
#Papers: 109
#Citation: 3200
H-Index: 27
G-Index: 56
Sociability: 6
Diversity: 0
Activity: 1
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn